BGI Group

Home
China
Shenzhen
BGI Group

BGI was founded privately in 1999 to participate in the renowned Human Genome Project.

BGI Group, a pioneer in life sciences, is one of the world’s leading biotechnology organizations with operations covering research, production, and applications in more than 100 countries and regions. It expanded scope through news business since 2007 and now it supports the genomics-related project with customers across the world.

11/03/2026

Professor Stephen J. O'Brien (Guy Harvey Oceanographic Center, Nova Southeastern University) offers a captivating look at the world of genomics! From his "Genome 10K" collaboration, he emphasizes that "genetics is part of every field of biology. And it just keeps getting better."

Looking ahead, he declares comparative genomics the next frontier, seeing BGI Group's advanced sequencing as pivotal to this pursuit. Future collaborations will leverage this capability to unravel complex biological questions and translate findings into medical breakthroughs.

09/03/2026

A new study from BGI-Research, in partnership with The Chinese University of Hong Kong, Shenzhen, has been published in Chemical Science. The research demonstrates a quantum–classical hybrid method (VQE-PDFT) for modeling electron transfer in the cryptochrome protein, overcoming key challenges in simulating complex biochemical systems. This achievement highlights the growing role of quantum computing in advancing biological research. Read more: https://en.genomics.cn/en-scientificdiscoverie-7475.html

05/03/2026

Hemogen Therapeutic has validated the SPARK global deployment model in Thailand with localized production of HGI-001 Injection (Hemo-cel) in collaboration with Chulalongkorn University.

SPARK is Hemogen Therapeutic’s integrated solution for establishing clinical-grade local manufacturing: technical guidance and training, the Celaxi-23 platform, standardized kits, regulatory frameworks, and structured technology transfer. This first international implementation shows that SPARK can move from concept to ex*****on, supporting reliable, compliant production closer to patients.

Hemogen Therapeutic is now extending SPARK across Southeast Asia and expanding partnerships in the Middle East to help build sustainable, scalable gene therapy ecosystems for thalassemia and inherited diseases.

Read more: https://en.genomics.cn/en-news-7474.html

04/03/2026

Hemogen Therapeutic’s investigational gene therapy, hemo-cel, has achieved promising results in a recently published study in Molecular Therapy. Conducted in collaboration with Shenzhen Children’s Hospital, the study showed that all participants with transfusion-dependent β-thalassemia reached transfusion independence, offering hope for a future with fewer treatment challenges. Learn more: https://en.genomics.cn/en-scientificdiscoverie-7472.html

02/03/2026

BGI-Research has developed a state-of-the-art nanopore sensing workflow for high-throughput peptide profiling and protein identification. Published in Nature Communications, this study integrates advanced AI analytics with innovative OPO library preparation to overcome key barriers in proteomics.

This scalable approach enables applications such as epitope mapping, antibody validation, and protein fingerprinting, with exciting potential for drug discovery and multi-omics research.

Discover more about this breakthrough: https://en.genomics.cn/en-scientificdiscoverie-7471.html

27/02/2026

BGI-Research and collaborators have published a study in Nature Communications looking at a basic question behind liquid biopsy testing: why do the DNA fragments circulating in blood tend to break in certain patterns, and why do those patterns differ across people?

By analyzing large-scale NIPT sequencing data, the team found that inherited genetics plays a meaningful role, and identified PANX1 as a key gene linked to these cfDNA fragment patterns, with additional experimental support.

Read more: https://en.genomics.cn/en-scientificdiscoverie-7470.html

25/02/2026

"This training will significantly improve technical capacity in South Sudan for disease surveillance and laboratory diagnosis, strengthening public health monitoring."

Mr. Reath highlights the immediate impact of the recent intensive workshop on pathogen detection and genome sequencing, hosted by China CDC and Africa CDC in Ethiopia. Six experts from BGI Group contributed innovative tools and methodologies, and he hopes to see a "very fruitful" partnership between BGI Group and his institute that will enhance South Sudan's public health capabilities and provide access to advanced technology.

23/02/2026

"This is a win-win partnership, a great way for us to challenge upcoming pandemics together." 🤝

Dr. Koné highlights the value of collaboration following the recent pathogen detection workshop hosted by China CDC and Africa CDC in Ethiopia. By sharing knowledge on innovative tools, BGI Group is always committed to supporting global health experts in building stronger genomic facilities.

20/02/2026

Mrs. Simushi shares her insights from the recent intensive workshop on pathogen detection and genome sequencing, hosted by China CDC and Africa CDC in Ethiopia. Six experts from BGI Group shared innovative tools and methodologies. She emphasizes how these advancements will enhance Zambia's outbreak response capabilities..

18/02/2026

"When I go back, I'm definitely going to transfer this knowledge and teach all my progress."

Dr. Embaló highlights the impact of the intensive workshop on pathogen detection and genome sequencing, hosted by China CDC and Africa CDC in Ethiopia. Six experts from BGI Group shared innovative tools and methodologies, participants like Dr. Embaló hope to enhance regional capacity through dedicated knowledge transfer.

16/02/2026

🌟 from Group! 🐎✨

We’re excited to welcome the ! Our Co-founder and Chairman Wang Jian sends his heartfelt greetings to all BGlers, their families, and our valued global partners.

Here’s to a filled with vitality, achievement, and prosperity. May this new year bring success and happiness to everyone!

13/02/2026

At ICG-20 Hangzhou, Professor Xifeng Wu from Zhejiang University highlights how population cohort studies are transforming public health. Her team leads the 'Healthy Zhejiang One Million People Cohort,' a massive initiative designed to unearth disease mechanisms and inform precise prevention and treatment strategies.

Prof. Wu emphasizes, "by leveraging cohort studies, we can identify effective biomarkers... applied across the entire spectrum of disease management." These biomarkers are valuable not only for diagnosis but also for prevention, screening, and personalized treatment plans, covering everything from healthy individuals to long-term patient outcomes.

She also details BGI Group's pivotal role: "BGI Group has taken genomic sequencing—which was once an expensive, exclusive research luxury—and transformed it into a scalable, widely accessible public technology." This provides a crucial foundation for large-scale scientific initiatives like their cohort, helping to accelerate the path towards a digitally-enabled system for comprehensive disease management and health.

Learn more about this vital initiative and its potential impact on improving population health:

Address

Building 11, Beishan Industrial Zone, Yantian District
Shenzhen
518083

Website

http://en.genomics.cn/index

Alerts

Be the first to know and let us send you an email when BGI Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BGI Group:

Shortcuts

Want your practice to be the top-listed Clinic in Shenzhen?